Structure of the catalytic domain of avian sarcoma virus integrase with a bound HIV-1 integrase-targeted inhibitor.

The x-ray structures of an inhibitor complex of the catalytic core domain of avian sarcoma virus integrase (ASV IN) were solved at 1.9- to 2.0-A resolution at two pH values, with and without Mn2+ cations. This inhibitor (Y-3), originally identified in a screen for inhibitors of the catalytic activity of HIV type 1 integrase (HIV-1 IN), was found in the present study to be active against ASV IN as well as HIV-1 IN. The Y-3 molecule is located in close proximity to the enzyme active site, interacts with the flexible loop, alters loop conformation, and affects the conformations of active site residues. As crystallized, a Y-3 molecule stacks against its symmetry-related mate. Preincubation of IN with metal cations does not prevent inhibition, and Y-3 binding does not prevent binding of divalent cations to IN. Three compounds chemically related to Y-3 also were investigated, but no binding was observed in the crystals. Our results identify the structural elements of the inhibitor that likely determine its binding properties.

[1]  The catalytic domain of human immunodeficiency virus integrase: ordered active site in the F185H mutant , 1996, FEBS letters.

[2]  A M Gronenborn,et al.  Solution structure of the DNA binding domain of HIV-1 integrase. , 1995, Biochemistry.

[3]  M C Nicklaus,et al.  HIV-1 integrase pharmacophore: discovery of inhibitors through three-dimensional database searching. , 1997, Journal of medicinal chemistry.

[4]  A. Brunger.  Free R value: a novel statistical quantity for assessing the accuracy of crystal structures. , 1992 .

[5]  M. Jaskólski,et al.  High-resolution structure of the catalytic domain of avian sarcoma virus integrase. , 1995, Journal of molecular biology.

[6]  A. Engelman,et al.  Crystal structure of the catalytic domain of HIV-1 integrase: similarity to other polynucleotidyl transferases. , 1994, Science.

[7]  A Wlodawer,et al.  Binding of Different Divalent Cations to the Active Site of Avian Sarcoma Virus Integrase and Their Effects on Enzymatic Activity* , 1997, The Journal of Biological Chemistry.

[8]  Lee Sp,et al.  Zinc stimulates Mg2+-dependent 3'-processing activity of human immunodeficiency virus type 1 integrase in vitro. , 1996 .

[9]  P. Brown,et al.  Reversal of integration and DNA splicing mediated by integrase of human immunodeficiency virus. , 1992, Science.

[10]  A. Gronenborn,et al.  Solution structure of the N-terminal zinc binding domain of HIV-1 integrase , 1997, Nature Structural Biology.

[11]  M. Jaskólski,et al.  The catalytic domain of avian sarcoma virus integrase: conformation of the active-site residues in the presence of divalent cations. , 1996, Structure.

[12]  M. Thomas,et al.  HIV integrase: a target for AIDS therapeutics. , 1997, Trends in biotechnology.

[13]  M S Lewis,et al.  Zn2+ promotes the self-association of human immunodeficiency virus type-1 integrase in vitro. , 1997, Biochemistry.

[14]  Axel T. Brunger,et al.  X-PLOR Version 3.1: A System for X-ray Crystallography and NMR , 1992 .

[15]  P. Brown,et al.  Mapping features of HIV-1 integrase near selected sites on viral and target DNA molecules in an active enzyme-DNA complex by photo-cross-linking. , 1997, Biochemistry.

[16]  A. Skalka,et al.  Activities and substrate specificity of the evolutionarily conserved central domain of retroviral integrase. , 1995, Virology.

[17]  A. Skalka,et al.  The retroviral enzymes. , 1994, Annual review of biochemistry.

[18]  Z. Otwinowski,et al.  [20] Processing of X-ray diffraction data collected in oscillation mode. , 1997, Methods in enzymology.

[19]  Y. Pommier,et al.  Design and discovery of HIV-1 integrase inhibitors , 1997 .

[20]  D. Hazuda,et al.  Equivalent inhibition of half-site and full-site retroviral strand transfer reactions by structurally diverse compounds , 1997, Journal of virology.

[21]  Y. Pommier,et al.  HIV-1 Integrase as a Target for Antiviral Drugs , 1997 .

[22]  A. Engelman,et al.  Critical contacts between HIV‐1 integrase and viral DNA identified by structure‐based analysis and photo‐crosslinking , 1997, The EMBO journal.

[23]  R. Plasterk,et al.  Characterization of the minimal DNA-binding domain of the HIV integrase protein. , 1994, Nucleic acids research.

[24]  S. Goff,et al.  Genetics of retroviral integration. , 1992, Annual review of genetics.

[25]  R. Plasterk,et al.  Identification of the catalytic and DNA-binding region of the human immunodeficiency virus type I integrase protein. , 1993, Nucleic acids research.

[26]  P. Kraulis.  A program to produce both detailed and schematic plots of protein structures , 1991 .

[27]  A. Engelman,et al.  The core and carboxyl-terminal domains of the integrase protein of human immunodeficiency virus type 1 each contribute to nonspecific DNA binding , 1994, Journal of virology.

[28]  G A Petsko,et al.  Aromatic-aromatic interaction: a mechanism of protein structure stabilization. , 1985, Science.

[29]  R. Craigie,et al.  Zinc folds the N-terminal domain of HIV-1 integrase, promotes multimerization, and enhances catalytic activity. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[30]  A. Skalka,et al.  Retroviral integrase domains: DNA binding and the recognition of LTR sequences. , 1991, Nucleic acids research.

[31]  F. Bushman,et al.  Differential inhibition of HIV-1 preintegration complexes and purified integrase protein by small molecules. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[32]  George W. A. Milne,et al.  National Cancer Institute Drug Information System 3D Database , 1994, J. Chem. Inf. Comput. Sci..

[33]  Rolf Boelens,et al.  The DNA-binding domain of HIV-1 integrase has an SH3-like fold , 1995, Nature Structural Biology.